<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296384</url>
  </required_header>
  <id_info>
    <org_study_id>P100134</org_study_id>
    <nct_id>NCT03296384</nct_id>
  </id_info>
  <brief_title>Influence of Environmental Factors and Schizophrenia</brief_title>
  <acronym>Envschi</acronym>
  <official_title>Influence of Environmental Factors on the Prevalence, Risk and the Clinical Manifestations of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut national d'étude démographique (INED)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPN (INSERM U894) CH Sainte-Anne - Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation FondaMental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a chronic and severe mental disorder with a lifetime prevalence of about 1&#xD;
      per cent, the symptoms can be very disabling and causing a heavy medical and socioeconomic.&#xD;
&#xD;
      There are significant variations from one population to another. Clinical manifestations of&#xD;
      schizophrenia (symptoms, evolution, severity of disability) are highly variable. This&#xD;
      variability, both epidemiological and clinical, is due to genetic and environmental factors.&#xD;
&#xD;
      Environmental factors may be either risk factors or modifying factors (changing clinical&#xD;
      presentation but do not alter the risk of disease) for schizophrenia.&#xD;
&#xD;
      Environmental risk factors have been identified (eg: urbanity, cannabis, migration), but the&#xD;
      investigators don't know neither the components directly responsible, nor the mechanisms by&#xD;
      which they increase the risk of schizophrenia.&#xD;
&#xD;
      To date, there is no study has systematically evaluated the role of environmental modifying&#xD;
      factors in schizophrenia.&#xD;
&#xD;
      Environmental factors may be individual, unique to each person (eg cannabis, migration.), or&#xD;
      population-based (eg ethnic density, socio-economic difficulties.) The identification/&#xD;
      identifying of environmental risk factors or modifiers, both individual and population, may&#xD;
      have theoretical implications (understanding of etiopathogenic mechanisms) and practical&#xD;
      (implementation of preventive measures). The potential effectiveness of preventive measures&#xD;
      is even greater than the risk attributable to certain environmental factors is important.&#xD;
&#xD;
      Most studies on environmental factors in schizophrenia were conducted in Anglo-Saxon&#xD;
      countries and northern Europe, but no study of these risk factors has been conducted in&#xD;
      France.&#xD;
&#xD;
      There are important differences environment based on study populations, these results are not&#xD;
      generalizable to other countries, including France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV)) will be estimated from the census population-unit (unit TRIRIS INSEE)</measure>
    <time_frame>56 months, From March 2014 to November 2018</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency of populational risk factors (insecurity, disorganization and density of migrants) will be assessed from the variables of INSEE</measure>
    <time_frame>56 months, From March 2014 to November 2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of individual risk factors (migration, cannabis, seasonality of birth, childhood trauma, social environment) will be measured from standardized assessments</measure>
    <time_frame>56 months, From March 2014 to November 2018</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Patients With Schizophrenia</condition>
  <condition>Relatives</condition>
  <arm_group>
    <arm_group_label>Patients with schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatives</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical and environmental evaluation</intervention_name>
    <description>For schizophrenic's patients, specific assessment will be perform</description>
    <arm_group_label>Patients with schizophrenia</arm_group_label>
    <arm_group_label>Relatives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Somatic state / condition and level of understanding (language, intellectual level)&#xD;
             compatible with the data collection (interview, self-administered questionnaires)&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Diagnosis of schizophrenia according to DSM-IV criteria&#xD;
&#xD;
          -  Living in catchment areas&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Not affiliated to the social security scheme&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
          -  Decompensated schizophrenic underway&#xD;
&#xD;
        Relatives&#xD;
&#xD;
          -  Protective Measures (tutor, curator)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  The diagnosis of psychotic disorder is not confirmed by the synthesis of all clinical&#xD;
             data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Schürhoff, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Michel Llorca, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Clermont Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Schürhoff, MD PhD</last_name>
    <phone>(0)1 49 81 30 50</phone>
    <phone_ext>+33</phone_ext>
    <email>franck.schurhoff@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrei Szoke, MD</last_name>
    <phone>(0)1 49 81 32 90</phone>
    <phone_ext>+33</phone_ext>
    <email>andrei.szoke@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>environmental factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

